Business Wire

OR-NUSCALE-POWER

9.12.2020 21:05:08 CET | Business Wire | Press release

Share
NuScale Power Releases Updated Evaluation for 77 MWe Module Clean Hydrogen Production

NuScale Power today announced updated evaluations for the technical feasibility and economics of producing hydrogen using heat and electricity from a NuScale Power Module™ (NPM) as a result of the recent announcement that an NPM can generate an additional 25 percent more power per module for a total of 250 MWt (or 77 MWe) per module. The hydrogen study was originally conducted in 2014 with the Idaho National Laboratory and has been updated with new production and economic parameters.

The updated analysis found that with the 25 percent increase in power output of an NPM, one 250 MWt NuScale module is capable of producing 2,053 kg/hour of hydrogen, or nearly 50 metric tons per day, an increase from 1,667 kg/hour of hydrogen or 40 metric tons per day for a 200 MWt NuScale module. Moreover, as a result of the lower levelized cost of electricity from the increased power output, hydrogen produced by a NuScale high-temperature steam electrolysis (HTSE) system is forecasted to be cost competitive with high capacity factor renewable hydrogen cost estimates while also providing continuous, controlled hydrogen production.

“The ability of our NPM to now produce even more clean hydrogen, in a smaller footprint, is yet another example of how NuScale’s technology can help decarbonize various sectors of the economy while providing additional revenue streams for customers,” said Dr. José Reyes, Chief Technology Officer and Co-founder of NuScale Power. “Coupled with our proven design, unparalleled safety, and load following capabilities, this analysis further demonstrates that NuScale’s design is the gold standard in helping meet the demand for innovative solutions to challenging global energy needs.”

In the analysis, energy from a single NPM in the form of superheated steam and electricity are directly routed to a HTSE system operating at 850°C. Only 2 percent of the electrical output (~1.8 MWe) of the NPM is used to increase the process steam temperature from 300°C at the NPM outlet to 850°C for the electrolyzer. NuScale’s innovative multi-module power plant design means that a NuScale plant could produce reliable clean electricity for the grid while allocating one or more modules to economically produce hydrogen when electricity demand is low.

According to a recent report from LucidCatalyst , in order for the world to meet the Paris goals of keeping warming between 1.5–2°C, sufficient, low-cost, clean hydrogen production is needed to replace oil and gas in shipping, aviation, and industry. Over 95% of the world's hydrogen is currently produced using fossil fuels, with the most common method being steam methane reforming from natural gas. Renewables cannot produce all of this hydrogen alone, and advanced modular reactors will be required to produce enough clean hydrogen to displace the 100 million barrels of oil that are currently consumed around the world each day. Using a single NPM to produce 50 tons of hydrogen per day would avoid about 460 tons of CO2 emissions per day, or 168,000 tons of CO2 per year, as compared to producing hydrogen from natural gas. Additionally, NuScale’s ability to produce clean hydrogen is perfectly suited to assist in decarbonizing transportation, since a single NPM can produce enough hydrogen to power 38,000 fuel cell vehicles or 1,500 long-haul fuel cell trucks at average annual fuel usage rates in the United States.

​​​​​About NuScale Power

NuScale Power has developed a new modular light water reactor nuclear power plant to supply energy for electrical generation, district heating, desalination, and other process heat applications. This groundbreaking small modular reactor (SMR) design features a fully factory-fabricated NuScale Power Module™ capable of generating 77 MW of electricity using a safer, smaller, and scalable version of pressurized water reactor technology. NuScale's scalable design—a power plant can house up to four, six, or 12 individual power modules—offers the benefits of carbon-free energy and reduces the financial commitments associated with gigawatt-sized nuclear facilities. The majority investor in NuScale is Fluor Corporation, a global engineering, procurement, and construction company with a 60-year history in commercial nuclear power.

NuScale is headquartered in Portland, OR and has offices in Corvallis, OR; Rockville, MD; Charlotte, NC; Richland, WA; and London, UK. Follow us on Twitter: @NuScale_Power , Facebook: NuScale Power, LLC , LinkedIn: NuScale-Power , and Instagram: nuscale_power . Visit NuScale’s website .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye